AnaptysBio (NASDAQ:ANAB) Stock Price Up 4.4% - What's Next?

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) shot up 4.4% on Thursday . The stock traded as high as $17.29 and last traded at $17.17. 85,418 shares were traded during mid-day trading, a decline of 84% from the average session volume of 533,342 shares. The stock had previously closed at $16.44.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ANAB. Guggenheim restated a "buy" rating on shares of AnaptysBio in a research note on Monday, March 3rd. Truist Financial reduced their price target on shares of AnaptysBio from $30.00 to $20.00 and set a "hold" rating for the company in a report on Wednesday, December 18th. BTIG Research downgraded shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. boosted their price objective on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $22.00 target price on shares of AnaptysBio in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $35.11.

AnaptysBio Price Performance

The company has a market capitalization of $538.21 million, a price-to-earnings ratio of -2.89 and a beta of 0.02. The stock has a fifty day simple moving average of $16.80 and a 200-day simple moving average of $22.47.

Remove Ads

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $43.11 million during the quarter, compared to analysts' expectations of $10.17 million. As a group, equities analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 65,184 shares of the firm's stock in a transaction dated Monday, December 30th. The shares were purchased at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the transaction, the director now directly owns 7,860,180 shares of the company's stock, valued at approximately $101,553,525.60. This represents a 0.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 33.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its position in shares of AnaptysBio by 131.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 1,531 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in AnaptysBio in the 4th quarter worth about $40,000. AlphaQuest LLC increased its stake in AnaptysBio by 1,891.5% during the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after buying an additional 4,237 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of AnaptysBio by 24.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 936 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after acquiring an additional 5,360 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.